Which has stronger valuation & earnings, PACS or WGS?

PACS Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PACS Group $5.29B 1.30 $191.54M $1.56 27.84 GeneDx $427.54M 4.51 -$21.02M -$2.68 N/A

Is PACS or WGS more profitable?

PACS Group has a net margin of 4.49% compared to GeneDx's net margin of -17.58%. PACS Group's return on equity of 26.47% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets PACS Group 4.49% 26.47% 4.36% GeneDx -17.58% 9.15% 5.21%

Does the media favor PACS or WGS?

In the previous week, GeneDx had 16 more articles in the media than PACS Group. MarketBeat recorded 29 mentions for GeneDx and 13 mentions for PACS Group. GeneDx's average media sentiment score of 0.09 beat PACS Group's score of 0.07 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PACS Group 3 Very Positive mention(s) 7 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeneDx 1 Very Positive mention(s) 1 Positive mention(s) 26 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, WGS or CELC?

GeneDx has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 4.51 -$21.02M -$2.68 N/A Celcuity N/A N/A -$177.04M -$3.90 N/A

Is WGS or CELC more profitable?

Celcuity has a net margin of 0.00% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -17.58% 9.15% 5.21% Celcuity N/A -244.61% -50.22%

Does the media refer more to WGS or CELC?

In the previous week, GeneDx had 25 more articles in the media than Celcuity. MarketBeat recorded 29 mentions for GeneDx and 4 mentions for Celcuity. Celcuity's average media sentiment score of 1.76 beat GeneDx's score of 0.09 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 1 Very Positive mention(s) 1 Positive mention(s) 26 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celcuity 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation & earnings, WGS or BLLN?

Billiontoone has lower revenue, but higher earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 4.51 -$21.02M -$2.68 N/A Billiontoone $305.11M 18.41 $7.45M $0.55 222.04

Does the media refer more to WGS or BLLN?

In the previous week, GeneDx had 15 more articles in the media than Billiontoone. MarketBeat recorded 29 mentions for GeneDx and 14 mentions for Billiontoone. GeneDx's average media sentiment score of 0.09 beat Billiontoone's score of -0.17 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 1 Very Positive mention(s) 1 Positive mention(s) 26 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Billiontoone 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, WGS or RDNT?

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 4.51 -$21.02M -$2.68 N/A RadNet $2.04B 2.42 -$18.65M -$0.18 N/A

Is WGS or RDNT more profitable?

RadNet has a net margin of -0.66% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -17.58% 9.15% 5.21% RadNet -0.66% 2.77% 0.97%

Does the media favor WGS or RDNT?

In the previous week, GeneDx had 26 more articles in the media than RadNet. MarketBeat recorded 29 mentions for GeneDx and 3 mentions for RadNet. RadNet's average media sentiment score of 1.38 beat GeneDx's score of 0.09 indicating that RadNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 1 Very Positive mention(s) 1 Positive mention(s) 26 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RadNet 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, SHC or WGS?

Sotera Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sotera Health $1.16B 4.34 $77.94M $0.41 43.16 GeneDx $427.54M 4.51 -$21.02M -$2.68 N/A

Is SHC or WGS more profitable?

Sotera Health has a net margin of 9.91% compared to GeneDx's net margin of -17.58%. Sotera Health's return on equity of 39.73% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 9.91% 39.73% 7.05% GeneDx -17.58% 9.15% 5.21%

Does the media prefer SHC or WGS?

In the previous week, GeneDx had 26 more articles in the media than Sotera Health. MarketBeat recorded 29 mentions for GeneDx and 3 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.83 beat GeneDx's score of 0.09 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GeneDx 1 Very Positive mention(s) 1 Positive mention(s) 26 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GeneDx (WGS) Competitors

$65.01 +1.16 (+1.82%)

As of 09:58 AM Eastern

Compare

WGS vs. PACS, CELC, BLLN, RDNT, and SHC

Should you buy GeneDx stock or one of its competitors? MarketBeat compares GeneDx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GeneDx include PACS Group (PACS), Celcuity (CELC), Billiontoone (BLLN), RadNet (RDNT), and Sotera Health (SHC). These companies are all part of the "healthcare" industry.

How does GeneDx compare to PACS Group?

PACS Group (NYSE:PACS) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

61.7% of GeneDx shares are held by institutional investors. 70.1% of PACS Group shares are held by company insiders. Comparatively, 25.2% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PACS Group has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, GeneDx has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

In the previous week, GeneDx had 16 more articles in the media than PACS Group. MarketBeat recorded 29 mentions for GeneDx and 13 mentions for PACS Group. GeneDx's average media sentiment score of 0.09 beat PACS Group's score of 0.07 indicating that GeneDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	3 Very Positive mention(s)	7 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeneDx	1 Very Positive mention(s)	1 Positive mention(s)	26 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PACS Group currently has a consensus price target of $50.60, indicating a potential upside of 16.50%. GeneDx has a consensus price target of $87.43, indicating a potential upside of 34.49%. Given GeneDx's higher probable upside, analysts plainly believe GeneDx is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
GeneDx	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

PACS Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29B	1.30	$191.54M	$1.56	27.84
GeneDx	$427.54M	4.51	-$21.02M	-$2.68	N/A

PACS Group has a net margin of 4.49% compared to GeneDx's net margin of -17.58%. PACS Group's return on equity of 26.47% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
GeneDx	-17.58%	9.15%	5.21%

Summary

PACS Group and GeneDx tied by winning 8 of the 16 factors compared between the two stocks.

How does GeneDx compare to Celcuity?

GeneDx (NASDAQ:WGS) and Celcuity (NASDAQ:CELC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

61.7% of GeneDx shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

GeneDx has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.51	-$21.02M	-$2.68	N/A
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

GeneDx currently has a consensus target price of $87.43, indicating a potential upside of 34.49%. Celcuity has a consensus target price of $152.09, indicating a potential upside of 45.42%. Given Celcuity's stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, GeneDx had 25 more articles in the media than Celcuity. MarketBeat recorded 29 mentions for GeneDx and 4 mentions for Celcuity. Celcuity's average media sentiment score of 1.76 beat GeneDx's score of 0.09 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	1 Very Positive mention(s)	1 Positive mention(s)	26 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celcuity	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

GeneDx has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

Celcuity has a net margin of 0.00% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Celcuity	N/A	-244.61%	-50.22%

Summary

GeneDx beats Celcuity on 9 of the 15 factors compared between the two stocks.

How does GeneDx compare to Billiontoone?

GeneDx (NASDAQ:WGS) and Billiontoone (NASDAQ:BLLN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Billiontoone has lower revenue, but higher earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.51	-$21.02M	-$2.68	N/A
Billiontoone	$305.11M	18.41	$7.45M	$0.55	222.04

In the previous week, GeneDx had 15 more articles in the media than Billiontoone. MarketBeat recorded 29 mentions for GeneDx and 14 mentions for Billiontoone. GeneDx's average media sentiment score of 0.09 beat Billiontoone's score of -0.17 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	1 Very Positive mention(s)	1 Positive mention(s)	26 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Billiontoone	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Billiontoone has a net margin of 0.00% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Billiontoone	N/A	N/A	N/A

61.7% of GeneDx shares are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GeneDx currently has a consensus price target of $87.43, suggesting a potential upside of 34.49%. Billiontoone has a consensus price target of $126.00, suggesting a potential upside of 3.17%. Given GeneDx's higher possible upside, equities analysts clearly believe GeneDx is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

GeneDx beats Billiontoone on 8 of the 13 factors compared between the two stocks.

How does GeneDx compare to RadNet?

GeneDx (NASDAQ:WGS) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, GeneDx had 26 more articles in the media than RadNet. MarketBeat recorded 29 mentions for GeneDx and 3 mentions for RadNet. RadNet's average media sentiment score of 1.38 beat GeneDx's score of 0.09 indicating that RadNet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	1 Very Positive mention(s)	1 Positive mention(s)	26 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RadNet	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.7% of GeneDx shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 25.2% of GeneDx shares are held by company insiders. Comparatively, 5.6% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.51	-$21.02M	-$2.68	N/A
RadNet	$2.04B	2.42	-$18.65M	-$0.18	N/A

GeneDx has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, RadNet has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

GeneDx currently has a consensus price target of $87.43, suggesting a potential upside of 34.49%. RadNet has a consensus price target of $87.43, suggesting a potential upside of 39.12%. Given RadNet's stronger consensus rating and higher probable upside, analysts clearly believe RadNet is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
RadNet	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

RadNet has a net margin of -0.66% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
RadNet	-0.66%	2.77%	0.97%

Summary

RadNet beats GeneDx on 9 of the 16 factors compared between the two stocks.

How does GeneDx compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

In the previous week, GeneDx had 26 more articles in the media than Sotera Health. MarketBeat recorded 29 mentions for GeneDx and 3 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.83 beat GeneDx's score of 0.09 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	1 Very Positive mention(s)	1 Positive mention(s)	26 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sotera Health has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

Sotera Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.34	$77.94M	$0.41	43.16
GeneDx	$427.54M	4.51	-$21.02M	-$2.68	N/A

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 15.4% of Sotera Health shares are held by company insiders. Comparatively, 25.2% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sotera Health currently has a consensus target price of $20.25, indicating a potential upside of 14.43%. GeneDx has a consensus target price of $87.43, indicating a potential upside of 34.49%. Given GeneDx's higher probable upside, analysts clearly believe GeneDx is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
GeneDx	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Sotera Health has a net margin of 9.91% compared to GeneDx's net margin of -17.58%. Sotera Health's return on equity of 39.73% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
GeneDx	-17.58%	9.15%	5.21%

Summary

Sotera Health beats GeneDx on 11 of the 16 factors compared between the two stocks.

Get GeneDx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WGS vs. The Competition

Export

Metric	GeneDx	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.91B	$9.60B	$7.05B	$12.61B
Dividend Yield	N/A	1.62%	2.68%	8.00%
P/E Ratio	-24.02	26.00	27.10	24.26
Price / Sales	4.51	17.40	588.85	117.88
Price / Cash	28.64	14.81	29.22	49.36
Price / Book	6.17	6.05	10.85	6.29
Net Income	-$21.02M	$177.20M	$3.58B	$330.66M
7 Day Performance	-0.63%	-2.07%	-2.12%	-1.35%
1 Month Performance	8.49%	6.96%	3.27%	-0.64%
1 Year Performance	-21.10%	11.42%	26.33%	19.08%

GeneDx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WGS GeneDx	4.033 of 5 stars	$65.01 +1.8%	$87.43 +34.5%	-22.7%	$1.91B	$427.54M	N/A	1,300
PACS PACS Group	3.3652 of 5 stars	$43.93 +0.7%	$50.60 +15.2%	+242.5%	$6.90B	$5.29B	28.16	47,455
CELC Celcuity	3.7078 of 5 stars	$108.90 -5.9%	$152.09 +39.7%	+661.5%	$5.64B	N/A	N/A	40	Positive News
BLLN Billiontoone	1.8833 of 5 stars	$120.60 +2.2%	$126.00 +4.5%	N/A	$5.43B	$305.11M	219.27	620	News Coverage Insider Trade
RDNT RadNet	3.6161 of 5 stars	$65.59 -3.3%	$87.43 +33.3%	+14.1%	$5.33B	$2.04B	N/A	11,264	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WGS) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeneDx (WGS) Competitors